<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00439647</url>
  </required_header>
  <id_info>
    <org_study_id>CZOL446M2309</org_study_id>
    <nct_id>NCT00439647</nct_id>
  </id_info>
  <brief_title>Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis</brief_title>
  <official_title>A Two Year Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Fracture Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Annually for the Treatment of Osteoporosis in Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will investigate if the drug zoledronic acid given once yearly is safe and has
      beneficial effects in treating osteoporosis by reducing bone loss and fractures in men with
      osteoporosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With at Least One New Morphometric Vertebral Fracture Over 24 Months</measure>
    <time_frame>24 Months</time_frame>
    <description>Vertebral fracture (VF) was assessed based on morphometry. QM(quantitative morphometry) incident VF(QM positive) is defined by at least 20% decrease in vertebral height of at least 4mm. If participant had QM positive at any vertebrae at any visit, x-rays from visits for participants were evaluated using Genant semi-quantitative method for VF assessment: Grade1 Mild VF is defined as 20-24% decrease in anterior, middle, and/or posterior vertebral height. Grade2 moderate VF is defined as 25-40% decrease in vertebral height. Grade3 Severe VF is defined as more than 40% decrease in vertebral height</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least One New Morphometric Vertebral Fracture Over 12 Months</measure>
    <time_frame>12 Months</time_frame>
    <description>Vertebral fracture (VF) was assessed based on morphometry. QM(quantitative morphometry) incident VF(QM positive) is defined by at least 20% decrease in vertebral height of at least 4mm. If participant had QM positive at any vertebrae at any visit, x-rays from visits for participants were evaluated using Genant semi-quantitative method for VF assessment: Grade1 Mild VF is defined as 20-24% decrease in anterior, middle, and/or posterior vertebral height. Grade2 moderate VF is defined as 25-40% decrease in vertebral height. Grade3 Severe VF is defined as more than 40% decrease in vertebral height</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least One New Moderate or Severe Morphometric Vertebral Fracture Over 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Moderate or severe vertebral fracture (VF) was assessed based on morphometry. A QM (quantitative morphometry) incident VF(QM positive) was defined by at least a 20% decrease in any vertebral height (at least 4 mm). If a participant had a QM positive at any vertebrae at any visit,x-rays from all visits for participants were evaluated using Genant semi-quantitative (SQ) method for VF assessment. Grade 2 moderate VF was defined as a 25-40% reduction in any vertebral height.Grade 3 Severe: VF was defined as more than 40% reduction in any vertebral height.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least One New Moderate or Severe Morphometric Vertebral Fracture Over 24 Months</measure>
    <time_frame>24 Months</time_frame>
    <description>Moderate or severe vertebral fracture (VF) was assessed based on morphometry. A QM (quantitative morphometry) incident VF(QM positive) was defined by at least a 20% decrease in any vertebral height (at least 4 mm). If a participant had a QM positive at any vertebrae at any visit,x-rays from all visits for participants were evaluated using Genant semi-quantitative (SQ) method for VF assessment. Grade 2 moderate VF was defined as a 25-40% reduction in any vertebral height.Grade 3 Severe: VF was defined as more than 40% reduction in any vertebral height.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least One New or Worsening Morphometric Vertebral Fracture Over 12 Months</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Worsening vertebral fracture (VF) was assessed based on morphometry. QM (quantitative morphometry) incident VF(QM positive) was defined by at least a 20% decrease in any vertebral height (at least 4 mm). If a participant had a QM positive at any vertebrae at any visit, x-rays from all visits for participants were evaluated using Genant semi-quantitative (SQ) method for VF assessment. A worsening fracture was defined as an SQ reading that was greater than the baseline SQ reading, which was at least 1 (prevalent fracture)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least One New or Worsening Morphometric Vertebral Fracture Over 24 Months</measure>
    <time_frame>Baseline, Month 24</time_frame>
    <description>Worsening vertebral fracture (VF) was assessed based on morphometry. A QM (quantitative morphometry) incident VF(QM positive) was defined by at least a 20% decrease in any vertebral height (at least 4 mm). If a participant had a QM positive at any vertebrae at any visit,x-rays from all visits for participants were evaluated using Genant semi-quantitative (SQ) method for VF assessment. A worsening fracture was defined as an SQ reading that was greater than the baseline SQ reading, which was at least 1 (prevalent fracture)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Height From Baseline</measure>
    <time_frame>from Baseline to 12 months and 24 months</time_frame>
    <description>Height was measured using a stadiometer. Two measurements were taken in millimeters (mm), and repeated if the two measurements differed by greater than 4 mm. The average of the two (or four) height measurements was used for analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Clinical Vertebral Fracture</measure>
    <time_frame>24 months</time_frame>
    <description>Clinical vertebral fracture is a painful vertebral fracture which came to clinical attention, e.g., with increased back pain, impairment of mobility or functional limitations. Subjects who did not experience a fracture event were censored at the end of study. End of study was defined as the last visit or date of death, whichever was earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Clinical Fracture</measure>
    <time_frame>24 months</time_frame>
    <description>Clinical fracture is painful fracture in any site which came to clinical attention, e.g., with increased pain, impaired mobility or functional limitations. Subjects who did not experience fracture were censored at end of study. End of study was defined as the earlier of last visit or date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Non-vertebral Fracture</measure>
    <time_frame>24 months</time_frame>
    <description>Non-vertebral fracture is any fracture which was not of the vertebrae. Subjects who did not experience a fracture event were censored at the end of study. End of study was defined as the last visit or date of death, whichever was earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Lumbar Spine Bone Mass Density (BMD)</measure>
    <time_frame>Month 6, Month 12, Month 24</time_frame>
    <description>Dual energy x-ray absorptiometry (DXA) Least Square Means (LSM) were analyzed using an ANCOVA model with treatment and baseline value as explanatory variables. Percent change in BMD at lumbar spine at Months 6, 12, and 24 relative to baseline as measured by DXA in a subset of at least 100 evaluable subjects at selected sites. Percentage change from baseline = 100*(endpoint - baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Total Hip BMD (g/CM^2)</measure>
    <time_frame>Month 6, Month 12, Month 24</time_frame>
    <description>Dual energy x-ray absorptiometry (DXA) Least Square Means (LSM) were analyzed using an ANCOVA model with treatment and baseline value as explanatory variables. Percent change in total hip BMD at Months 6, 12, and 24 relative to baseline as measured by DXA in a subset of at least 100 evaluable subjects at selected sites. Percentage change from baseline = 100*(endpoint - baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Femoral Neck BMD (g/CM^2)</measure>
    <time_frame>Month 6, Month 12, Month 24</time_frame>
    <description>Dual energy x-ray absorptiometry (DXA) Least Square Means (LSM) were analyzed using an ANCOVA model with treatment and baseline value as explanatory variables. Percent change in total femoral neck BMD at Months 6, 12, and 24 relative to baseline as measured by DXA in a subset of at least 100 evaluable subjects at selected sites. Percentage change from baseline = 100*(endpoint - baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Beta C-terminal Telopeptides of Type I Collagen(b-CTx) by Visits</measure>
    <time_frame>Baseline, Month 3, Month 6, Month 12, Month 15, month 18, Month 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1199</enrollment>
  <condition>Male Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Zoledronic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The i.v. infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid 5 mg iv</intervention_name>
    <description>Zoledronic acid 5 mg iv given once a year.</description>
    <arm_group_label>Zoledronic Acid</arm_group_label>
    <other_name>Aclasta,</other_name>
    <other_name>Reclast</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo intravenous (i.v.) once a year</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Osteoporosis as defined by very low bone mineral density in the hip and spine or low bone
        mineral density in the hip combined with presence of 1-3 mild or moderate fractures of the
        vertebrae

        Exclusion Criteria:

          -  Low Vitamin D

          -  Renal insufficiency

          -  Previous treatment with certain anti-osteoporotic therapies (except after certain
             washout periods): calcitonin, bisphosphonates, parathyroid hormone (PTH), sodium
             fluoride, strontium ranelate,

          -  Previous treatment with testosterone, anabolic steroids or growth hormone

          -  Chronic use of systemic corticosteroids (oral or i.v.) within the last year

          -  History of any cancer or metastases within the last 5 years

          -  History of brittle bone disease, multiple myeloma, or Paget's disease, or any other
             metabolic bone disease, except osteoporosis

          -  Bilateral hip replacements

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis Argentina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis Czech Republic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis Hungary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis Portugal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis Romania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis Slovakia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis United Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis Austria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis Iceland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis Russia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis (South Africa)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Geelong-VIC</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maroochydore-QLD</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Randwick-NSW</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Diepenbeek</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Godinne</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gozee</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jette</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Laeken</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Merksem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wilrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brasilia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ceske Budejovice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plzen</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glostrup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Odense C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Bentheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Pyrmont</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Braunfels</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kempen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leverkusen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szekesfehervar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Veszprem</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Kopavogur</city>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Arenzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Siena-SI</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Valeggio Sul Mincio</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Elverum</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gjettum</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamar</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paradis</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ponte de Lima</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cluj Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Tyumen</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Yekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Lubochna</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Piestany</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Rosebank-Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Western Cape</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Merida</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sabadell</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villajoyosa</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Linkoeping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Malmo</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Orebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Umea</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aarau</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baden</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Geneve</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Sion</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Chorley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Middx</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Penarth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Reading-Berkshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Iceland</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2007</study_first_submitted>
  <study_first_submitted_qc>February 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2007</study_first_posted>
  <results_first_submitted>October 10, 2011</results_first_submitted>
  <results_first_submitted_qc>October 10, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 16, 2011</results_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>males</keyword>
  <keyword>vertebral fractures</keyword>
  <keyword>clinical fractures</keyword>
  <keyword>bone mineral density</keyword>
  <keyword>bone biomarkers</keyword>
  <keyword>zoledronic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Zoledronic Acid</title>
          <description>5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="588">&quot;Started&quot; indicates intent to treat (ITT) and safety set.</participants>
                <participants group_id="P2" count="611"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified Intent to Treat (mITT)</title>
              <participants_list>
                <participants group_id="P1" count="553"/>
                <participants group_id="P2" count="574"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="530"/>
                <participants group_id="P2" count="540"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zoledronic Acid</title>
          <description>5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="588"/>
            <count group_id="B2" value="611"/>
            <count group_id="B3" value="1199"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.8" spread="8.3"/>
                    <measurement group_id="B2" value="65.7" spread="8.6"/>
                    <measurement group_id="B3" value="65.8" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="588"/>
                    <measurement group_id="B2" value="611"/>
                    <measurement group_id="B3" value="1199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least One New Morphometric Vertebral Fracture Over 24 Months</title>
        <description>Vertebral fracture (VF) was assessed based on morphometry. QM(quantitative morphometry) incident VF(QM positive) is defined by at least 20% decrease in vertebral height of at least 4mm. If participant had QM positive at any vertebrae at any visit, x-rays from visits for participants were evaluated using Genant semi-quantitative method for VF assessment: Grade1 Mild VF is defined as 20-24% decrease in anterior, middle, and/or posterior vertebral height. Grade2 moderate VF is defined as 25-40% decrease in vertebral height. Grade3 Severe VF is defined as more than 40% decrease in vertebral height</description>
        <time_frame>24 Months</time_frame>
        <population>Modified Intent-to-treat (mITT) population included all randomized subjects who had a baseline and at least one post-baseline assessment of the primary efficacy variable. In this analysis, missing Month 24 fractures were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid</title>
            <description>5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One New Morphometric Vertebral Fracture Over 24 Months</title>
          <description>Vertebral fracture (VF) was assessed based on morphometry. QM(quantitative morphometry) incident VF(QM positive) is defined by at least 20% decrease in vertebral height of at least 4mm. If participant had QM positive at any vertebrae at any visit, x-rays from visits for participants were evaluated using Genant semi-quantitative method for VF assessment: Grade1 Mild VF is defined as 20-24% decrease in anterior, middle, and/or posterior vertebral height. Grade2 moderate VF is defined as 25-40% decrease in vertebral height. Grade3 Severe VF is defined as more than 40% decrease in vertebral height</description>
          <population>Modified Intent-to-treat (mITT) population included all randomized subjects who had a baseline and at least one post-baseline assessment of the primary efficacy variable. In this analysis, missing Month 24 fractures were imputed using LOCF.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="553"/>
                <count group_id="O2" value="574"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least One New Morphometric Vertebral Fracture Over 12 Months</title>
        <description>Vertebral fracture (VF) was assessed based on morphometry. QM(quantitative morphometry) incident VF(QM positive) is defined by at least 20% decrease in vertebral height of at least 4mm. If participant had QM positive at any vertebrae at any visit, x-rays from visits for participants were evaluated using Genant semi-quantitative method for VF assessment: Grade1 Mild VF is defined as 20-24% decrease in anterior, middle, and/or posterior vertebral height. Grade2 moderate VF is defined as 25-40% decrease in vertebral height. Grade3 Severe VF is defined as more than 40% decrease in vertebral height</description>
        <time_frame>12 Months</time_frame>
        <population>Modified Intent-to-treat (mITT) population included all randomized subjects who had a baseline and at least one post-baseline assessment of the primary efficacy variable. Patients with a baseline x-ray and a 12M x-ray are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid</title>
            <description>5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One New Morphometric Vertebral Fracture Over 12 Months</title>
          <description>Vertebral fracture (VF) was assessed based on morphometry. QM(quantitative morphometry) incident VF(QM positive) is defined by at least 20% decrease in vertebral height of at least 4mm. If participant had QM positive at any vertebrae at any visit, x-rays from visits for participants were evaluated using Genant semi-quantitative method for VF assessment: Grade1 Mild VF is defined as 20-24% decrease in anterior, middle, and/or posterior vertebral height. Grade2 moderate VF is defined as 25-40% decrease in vertebral height. Grade3 Severe VF is defined as more than 40% decrease in vertebral height</description>
          <population>Modified Intent-to-treat (mITT) population included all randomized subjects who had a baseline and at least one post-baseline assessment of the primary efficacy variable. Patients with a baseline x-ray and a 12M x-ray are included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="553"/>
                <count group_id="O2" value="574"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least One New Moderate or Severe Morphometric Vertebral Fracture Over 12 Months</title>
        <description>Moderate or severe vertebral fracture (VF) was assessed based on morphometry. A QM (quantitative morphometry) incident VF(QM positive) was defined by at least a 20% decrease in any vertebral height (at least 4 mm). If a participant had a QM positive at any vertebrae at any visit,x-rays from all visits for participants were evaluated using Genant semi-quantitative (SQ) method for VF assessment. Grade 2 moderate VF was defined as a 25-40% reduction in any vertebral height.Grade 3 Severe: VF was defined as more than 40% reduction in any vertebral height.</description>
        <time_frame>12 months</time_frame>
        <population>Modified Intent-to-treat (mITT) population included all randomized subjects who had a baseline and at least one post-baseline assessment of the primary efficacy variable. Patients with a baseline x-ray and a 12M x-ray are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid</title>
            <description>5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One New Moderate or Severe Morphometric Vertebral Fracture Over 12 Months</title>
          <description>Moderate or severe vertebral fracture (VF) was assessed based on morphometry. A QM (quantitative morphometry) incident VF(QM positive) was defined by at least a 20% decrease in any vertebral height (at least 4 mm). If a participant had a QM positive at any vertebrae at any visit,x-rays from all visits for participants were evaluated using Genant semi-quantitative (SQ) method for VF assessment. Grade 2 moderate VF was defined as a 25-40% reduction in any vertebral height.Grade 3 Severe: VF was defined as more than 40% reduction in any vertebral height.</description>
          <population>Modified Intent-to-treat (mITT) population included all randomized subjects who had a baseline and at least one post-baseline assessment of the primary efficacy variable. Patients with a baseline x-ray and a 12M x-ray are included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="553"/>
                <count group_id="O2" value="574"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least One New Moderate or Severe Morphometric Vertebral Fracture Over 24 Months</title>
        <description>Moderate or severe vertebral fracture (VF) was assessed based on morphometry. A QM (quantitative morphometry) incident VF(QM positive) was defined by at least a 20% decrease in any vertebral height (at least 4 mm). If a participant had a QM positive at any vertebrae at any visit,x-rays from all visits for participants were evaluated using Genant semi-quantitative (SQ) method for VF assessment. Grade 2 moderate VF was defined as a 25-40% reduction in any vertebral height.Grade 3 Severe: VF was defined as more than 40% reduction in any vertebral height.</description>
        <time_frame>24 Months</time_frame>
        <population>Modified Intent-to-treat (mITT) population included all randomized subjects who had a baseline and at least one post-baseline assessment of the primary efficacy variable. Patients with a baseline x-ray and a 12M x-ray are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid</title>
            <description>5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One New Moderate or Severe Morphometric Vertebral Fracture Over 24 Months</title>
          <description>Moderate or severe vertebral fracture (VF) was assessed based on morphometry. A QM (quantitative morphometry) incident VF(QM positive) was defined by at least a 20% decrease in any vertebral height (at least 4 mm). If a participant had a QM positive at any vertebrae at any visit,x-rays from all visits for participants were evaluated using Genant semi-quantitative (SQ) method for VF assessment. Grade 2 moderate VF was defined as a 25-40% reduction in any vertebral height.Grade 3 Severe: VF was defined as more than 40% reduction in any vertebral height.</description>
          <population>Modified Intent-to-treat (mITT) population included all randomized subjects who had a baseline and at least one post-baseline assessment of the primary efficacy variable. Patients with a baseline x-ray and a 12M x-ray are included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="553"/>
                <count group_id="O2" value="574"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least One New or Worsening Morphometric Vertebral Fracture Over 12 Months</title>
        <description>Worsening vertebral fracture (VF) was assessed based on morphometry. QM (quantitative morphometry) incident VF(QM positive) was defined by at least a 20% decrease in any vertebral height (at least 4 mm). If a participant had a QM positive at any vertebrae at any visit, x-rays from all visits for participants were evaluated using Genant semi-quantitative (SQ) method for VF assessment. A worsening fracture was defined as an SQ reading that was greater than the baseline SQ reading, which was at least 1 (prevalent fracture)</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>Modified Intent-to-treat (mITT) population included all randomized subjects who had a baseline and at least one post-baseline assessment of the primary efficacy variable. Patients with a baseline x-ray and a 12M x-ray are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid</title>
            <description>5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One New or Worsening Morphometric Vertebral Fracture Over 12 Months</title>
          <description>Worsening vertebral fracture (VF) was assessed based on morphometry. QM (quantitative morphometry) incident VF(QM positive) was defined by at least a 20% decrease in any vertebral height (at least 4 mm). If a participant had a QM positive at any vertebrae at any visit, x-rays from all visits for participants were evaluated using Genant semi-quantitative (SQ) method for VF assessment. A worsening fracture was defined as an SQ reading that was greater than the baseline SQ reading, which was at least 1 (prevalent fracture)</description>
          <population>Modified Intent-to-treat (mITT) population included all randomized subjects who had a baseline and at least one post-baseline assessment of the primary efficacy variable. Patients with a baseline x-ray and a 12M x-ray are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="553"/>
                <count group_id="O2" value="574"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least One New or Worsening Morphometric Vertebral Fracture Over 24 Months</title>
        <description>Worsening vertebral fracture (VF) was assessed based on morphometry. A QM (quantitative morphometry) incident VF(QM positive) was defined by at least a 20% decrease in any vertebral height (at least 4 mm). If a participant had a QM positive at any vertebrae at any visit,x-rays from all visits for participants were evaluated using Genant semi-quantitative (SQ) method for VF assessment. A worsening fracture was defined as an SQ reading that was greater than the baseline SQ reading, which was at least 1 (prevalent fracture)</description>
        <time_frame>Baseline, Month 24</time_frame>
        <population>Modified Intent-to-treat (mITT) population included all randomized subjects who had a baseline and at least one post-baseline assessment of the primary efficacy variable. In this analysis, missing Month 24 fractures were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid</title>
            <description>5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One New or Worsening Morphometric Vertebral Fracture Over 24 Months</title>
          <description>Worsening vertebral fracture (VF) was assessed based on morphometry. A QM (quantitative morphometry) incident VF(QM positive) was defined by at least a 20% decrease in any vertebral height (at least 4 mm). If a participant had a QM positive at any vertebrae at any visit,x-rays from all visits for participants were evaluated using Genant semi-quantitative (SQ) method for VF assessment. A worsening fracture was defined as an SQ reading that was greater than the baseline SQ reading, which was at least 1 (prevalent fracture)</description>
          <population>Modified Intent-to-treat (mITT) population included all randomized subjects who had a baseline and at least one post-baseline assessment of the primary efficacy variable. In this analysis, missing Month 24 fractures were imputed using LOCF.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="553"/>
                <count group_id="O2" value="574"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Height From Baseline</title>
        <description>Height was measured using a stadiometer. Two measurements were taken in millimeters (mm), and repeated if the two measurements differed by greater than 4 mm. The average of the two (or four) height measurements was used for analysis</description>
        <time_frame>from Baseline to 12 months and 24 months</time_frame>
        <population>Modified Intent-to-treat (mITT) population included all randomized subjects who had a baseline and at least one post-baseline assessment of the primary efficacy variable. Patients with a baseline x-ray and a 12M x-ray are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid</title>
            <description>5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Height From Baseline</title>
          <description>Height was measured using a stadiometer. Two measurements were taken in millimeters (mm), and repeated if the two measurements differed by greater than 4 mm. The average of the two (or four) height measurements was used for analysis</description>
          <population>Modified Intent-to-treat (mITT) population included all randomized subjects who had a baseline and at least one post-baseline assessment of the primary efficacy variable. Patients with a baseline x-ray and a 12M x-ray are included.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="0.333"/>
                    <measurement group_id="O2" value="-2.50" spread="0.522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.33" spread="0.389"/>
                    <measurement group_id="O2" value="-4.61" spread="0.610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Clinical Vertebral Fracture</title>
        <description>Clinical vertebral fracture is a painful vertebral fracture which came to clinical attention, e.g., with increased back pain, impairment of mobility or functional limitations. Subjects who did not experience a fracture event were censored at the end of study. End of study was defined as the last visit or date of death, whichever was earlier.</description>
        <time_frame>24 months</time_frame>
        <population>The ITT (intent to treat) population consisted of all subjects as randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid</title>
            <description>5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Clinical Vertebral Fracture</title>
          <description>Clinical vertebral fracture is a painful vertebral fracture which came to clinical attention, e.g., with increased back pain, impairment of mobility or functional limitations. Subjects who did not experience a fracture event were censored at the end of study. End of study was defined as the last visit or date of death, whichever was earlier.</description>
          <population>The ITT (intent to treat) population consisted of all subjects as randomized.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="588"/>
                <count group_id="O2" value="611"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Clinical Fracture</title>
        <description>Clinical fracture is painful fracture in any site which came to clinical attention, e.g., with increased pain, impaired mobility or functional limitations. Subjects who did not experience fracture were censored at end of study. End of study was defined as the earlier of last visit or date of death.</description>
        <time_frame>24 months</time_frame>
        <population>The ITT (intent to treat) population consisted of all subjects as randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid</title>
            <description>5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Clinical Fracture</title>
          <description>Clinical fracture is painful fracture in any site which came to clinical attention, e.g., with increased pain, impaired mobility or functional limitations. Subjects who did not experience fracture were censored at end of study. End of study was defined as the earlier of last visit or date of death.</description>
          <population>The ITT (intent to treat) population consisted of all subjects as randomized.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="588"/>
                <count group_id="O2" value="611"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="1.95"/>
                    <measurement group_id="O2" value="11" spread="3.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Non-vertebral Fracture</title>
        <description>Non-vertebral fracture is any fracture which was not of the vertebrae. Subjects who did not experience a fracture event were censored at the end of study. End of study was defined as the last visit or date of death, whichever was earlier.</description>
        <time_frame>24 months</time_frame>
        <population>The ITT (intent to treat) population consisted of all subjects as randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid</title>
            <description>5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Non-vertebral Fracture</title>
          <description>Non-vertebral fracture is any fracture which was not of the vertebrae. Subjects who did not experience a fracture event were censored at the end of study. End of study was defined as the last visit or date of death, whichever was earlier.</description>
          <population>The ITT (intent to treat) population consisted of all subjects as randomized.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="588"/>
                <count group_id="O2" value="611"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="1.88"/>
                    <measurement group_id="O2" value="8" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Lumbar Spine Bone Mass Density (BMD)</title>
        <description>Dual energy x-ray absorptiometry (DXA) Least Square Means (LSM) were analyzed using an ANCOVA model with treatment and baseline value as explanatory variables. Percent change in BMD at lumbar spine at Months 6, 12, and 24 relative to baseline as measured by DXA in a subset of at least 100 evaluable subjects at selected sites. Percentage change from baseline = 100*(endpoint - baseline)</description>
        <time_frame>Month 6, Month 12, Month 24</time_frame>
        <population>Intent-to-treat (ITT) population included all randomized subjects who had a baseline and at least one post-baseline assessment of the efficacy variable.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid</title>
            <description>5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Lumbar Spine Bone Mass Density (BMD)</title>
          <description>Dual energy x-ray absorptiometry (DXA) Least Square Means (LSM) were analyzed using an ANCOVA model with treatment and baseline value as explanatory variables. Percent change in BMD at lumbar spine at Months 6, 12, and 24 relative to baseline as measured by DXA in a subset of at least 100 evaluable subjects at selected sites. Percentage change from baseline = 100*(endpoint - baseline)</description>
          <population>Intent-to-treat (ITT) population included all randomized subjects who had a baseline and at least one post-baseline assessment of the efficacy variable.</population>
          <units>Percent change in BMD</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 (n=61, n=61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.87" spread="0.412"/>
                    <measurement group_id="O2" value="0.10" spread="0.412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=60, n=62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.51" spread="0.437"/>
                    <measurement group_id="O2" value="0.84" spread="0.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=58, n=61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.73" spread="0.459"/>
                    <measurement group_id="O2" value="1.61" spread="0.448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Total Hip BMD (g/CM^2)</title>
        <description>Dual energy x-ray absorptiometry (DXA) Least Square Means (LSM) were analyzed using an ANCOVA model with treatment and baseline value as explanatory variables. Percent change in total hip BMD at Months 6, 12, and 24 relative to baseline as measured by DXA in a subset of at least 100 evaluable subjects at selected sites. Percentage change from baseline = 100*(endpoint - baseline)</description>
        <time_frame>Month 6, Month 12, Month 24</time_frame>
        <population>Intent-to-treat (ITT) population included all randomized subjects who had a baseline and at least one post-baseline assessment of the efficacy variable.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid</title>
            <description>5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Total Hip BMD (g/CM^2)</title>
          <description>Dual energy x-ray absorptiometry (DXA) Least Square Means (LSM) were analyzed using an ANCOVA model with treatment and baseline value as explanatory variables. Percent change in total hip BMD at Months 6, 12, and 24 relative to baseline as measured by DXA in a subset of at least 100 evaluable subjects at selected sites. Percentage change from baseline = 100*(endpoint - baseline)</description>
          <population>Intent-to-treat (ITT) population included all randomized subjects who had a baseline and at least one post-baseline assessment of the efficacy variable.</population>
          <units>Percent change in BMD</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 (n=60, n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="0.294"/>
                    <measurement group_id="O2" value="-0.44" spread="0.287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=58, n=64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" spread="0.283"/>
                    <measurement group_id="O2" value="0.26" spread="0.269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=56, n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" spread="0.346"/>
                    <measurement group_id="O2" value="0.16" spread="0.326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Femoral Neck BMD (g/CM^2)</title>
        <description>Dual energy x-ray absorptiometry (DXA) Least Square Means (LSM) were analyzed using an ANCOVA model with treatment and baseline value as explanatory variables. Percent change in total femoral neck BMD at Months 6, 12, and 24 relative to baseline as measured by DXA in a subset of at least 100 evaluable subjects at selected sites. Percentage change from baseline = 100*(endpoint - baseline)</description>
        <time_frame>Month 6, Month 12, Month 24</time_frame>
        <population>Intent-to-treat (ITT) population included all randomized subjects who had a baseline and at least one post-baseline assessment of the efficacy variable.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid</title>
            <description>5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Femoral Neck BMD (g/CM^2)</title>
          <description>Dual energy x-ray absorptiometry (DXA) Least Square Means (LSM) were analyzed using an ANCOVA model with treatment and baseline value as explanatory variables. Percent change in total femoral neck BMD at Months 6, 12, and 24 relative to baseline as measured by DXA in a subset of at least 100 evaluable subjects at selected sites. Percentage change from baseline = 100*(endpoint - baseline)</description>
          <population>Intent-to-treat (ITT) population included all randomized subjects who had a baseline and at least one post-baseline assessment of the efficacy variable.</population>
          <units>Percent change in BMD</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 (n=60, n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" spread="0.448"/>
                    <measurement group_id="O2" value="0.58" spread="0.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=58, n=64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.06" spread="0.465"/>
                    <measurement group_id="O2" value="0.59" spread="0.443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=56, n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39" spread="0.544"/>
                    <measurement group_id="O2" value="0.09" spread="0.513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Beta C-terminal Telopeptides of Type I Collagen(b-CTx) by Visits</title>
        <time_frame>Baseline, Month 3, Month 6, Month 12, Month 15, month 18, Month 24</time_frame>
        <population>The ITT, Intent to Treat population, includes all participants who received a single a dose of treatment and had data available for analysis. n = the number of subjects with evaluable measurements at visit, as determined by the efficacy window.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid</title>
            <description>5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Beta C-terminal Telopeptides of Type I Collagen(b-CTx) by Visits</title>
          <population>The ITT, Intent to Treat population, includes all participants who received a single a dose of treatment and had data available for analysis. n = the number of subjects with evaluable measurements at visit, as determined by the efficacy window.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n-64) (n=66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3646" spread="0.02094"/>
                    <measurement group_id="O2" value="0.3933" spread="0.02955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=63) (n=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0990" spread="0.00800" lower_limit="0.22" upper_limit="0.31"/>
                    <measurement group_id="O2" value="0.3647" spread="0.02989" lower_limit="0.22" upper_limit="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=62) (n=64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1384" spread="0.00914" lower_limit="0.34" upper_limit="0.47"/>
                    <measurement group_id="O2" value="0.3540" spread="0.02576" lower_limit="0.34" upper_limit="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=63) (n=64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1669" spread="0.00925" lower_limit="0.38" upper_limit="0.53"/>
                    <measurement group_id="O2" value="0.4042" spread="0.03056" lower_limit="0.38" upper_limit="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15 (n=55) (n=58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0996" spread="0.00590"/>
                    <measurement group_id="O2" value="0.3576" spread="0.02519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n=55) (n=60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1320" spread="0.00661"/>
                    <measurement group_id="O2" value="0.3954" spread="0.03001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=55) (n=62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1760" spread="0.01248" lower_limit="0.38" upper_limit="0.52"/>
                    <measurement group_id="O2" value="0.4060" spread="0.02640" lower_limit="0.38" upper_limit="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Zoledronic Acid</title>
          <description>5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The i.v. infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The i.v. infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="154" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pernicious anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Exomphalos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Heterophoria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Retinal degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Femoral hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Intestinal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Poor dental condition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Incision site abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Traumatic lung injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Vascular graft complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Bunion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Spondyloarthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Bladder cancer stage 0, with cancer in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Brain neoplasm benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Hypopharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Lymph node cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Metastases to the mediastinum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Oesophageal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer extensive stage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol induced persisting dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Brain compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cerebral atrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cervical root pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Radicular pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Encopresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder neck obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Microalbuminuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Urethral polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Epididymal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Testicular swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Foreign body aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Lung consolidation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Walking disability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Arteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Vascular calcification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="399" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="256" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial; or the publication of the trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Novartis Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

